Drug Trial Radar · NCT05615974
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
139
Planned (sponsor's estimate)
Start
Jan 11, 2023
Primary completion
Jan 11, 2027
Study completion Jan 11, 2028
Sponsor
- Lead sponsor
- LaNova Medicines LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD) and/or the recommended phase 2 dose (RP2D) of LM-101 as a single agent or in combination in patients with advanced malignant tumors
Conditions
- Malignant Tumors
Interventions
LM101Drug
Administered intravenously
ToripalimabDrug
Administered intravenously
RituximabDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: 48 weeks
- Incidence of dose-limitingtoxicity (DLT)Time frame: 48 weeks
- Incidence of serious adverse event (SAE)Time frame: 48 weeks
- Temperature in ℃Time frame: 48 weeks
- Pulse in BPM(Beat per Minute)Time frame: 48 weeks
- Blood Pressure in mmHgTime frame: 48 weeks
- Weight in KgTime frame: 48 weeks
- Height in centimeterTime frame: 48 weeks
- Laboratory tests-Blood Routine examinationTime frame: 48 weeks
- Laboratory tests-Urine Routine testTime frame: 48 weeks
- Laboratory tests-Blood biochemistryTime frame: 48 weeks
- Laboratory tests- Coangulation functionTime frame: 48 weeks
- Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentageTime frame: 48 weeks
- 12-lead electrocardiogram (ECG) in QTcF.Time frame: 48 weeks
- 12-lead electrocardiogram (ECG) in QT.Time frame: 48 weeks
- 12-lead electrocardiogram (ECG) in QRS.Time frame: 48 weeks
- 12-lead electrocardiogram (ECG) in HR.Time frame: 48 weeks
- 12-lead electrocardiogram (ECG) in RR.Time frame: 48 weeks
- 12-lead electrocardiogram (ECG) in PR.Time frame: 48 weeks
- ECOG(Eastern Cooperative Oncology Group) scoreTime frame: 48 weeks
- Overall Response Rate (ORR)Time frame: 64 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital, CMU
Beijing, China · Terminated
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Recruiting
Linyi Cancer Hospital
Linyi, Shandong, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.